ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Patents and technology transfer in CRISPR technology | JoVE Visualize

Home
Research Domains
Information And Computing Sciences

Patents and technology transfer in CRISPR technology

Lichelle Grobler¹, Essa Suleman², Deepak B Thimiri Govinda Raj¹

¹Synthetic Nanobiotechnology and Biomachines Group, ERA Synthetic Biology, Centre for Synthetic Biology and Precision Medicine, CSIR, Pretoria, South Africa.

Progress in Molecular Biology and Translational Science|May 3, 2021

View abstract on PubMed

Summary

CRISPR technology offers diverse applications across industries, with a focus on non-mammalian systems. This chapter explores CRISPR nucleases, patent landscapes, and diagnostic company case studies for SARS-CoV-2 detection.

Area of Science:

CRISPR technology
Molecular biology
Biotechnology

Background:

CRISPR systems have revolutionized biological research and seen extensive patenting.
Commercial applications are emerging despite technology transfer pressures.
Patents cover diverse CRISPR applications in agriculture, synthetic biology, and medicine.

Purpose of the Study:

To discuss CRISPR nucleases and their applications.
To provide an opinion on the CRISPR patent and technology landscape for non-mammalian systems.
To identify future advancements and challenges for CRISPR in non-mammalian systems.

Main Methods:

Review of CRISPR nucleases and their applications.
Analysis of the CRISPR patent landscape for non-mammalian systems.
Case studies of CRISPR diagnostics companies (SHERLOCK and Mammoth Biosciences) for SARS-CoV-2 detection.

Main Results:

CRISPR technology has a broad patent landscape with commercial applications emerging.
SHERLOCK and Mammoth Biosciences are leaders in developing CRISPR-based diagnostics for SARS-CoV-2.
Future advancements and challenges in non-mammalian CRISPR systems are identified.

Conclusions:

CRISPR technology presents significant opportunities and challenges in non-mammalian systems.
The patent landscape is complex but driving commercial innovation.
CRISPR-based diagnostics show promise for rapid disease detection.

Keywords:

Distributed Computing And Systems Software

Concurrent/parallel Systems And Technologies

Patents And Technology Transfer In Crispr Technology

Mammoth biosciences

Non-mammalian system